AU8071698A - Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction - Google Patents

Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction

Info

Publication number
AU8071698A
AU8071698A AU80716/98A AU8071698A AU8071698A AU 8071698 A AU8071698 A AU 8071698A AU 80716/98 A AU80716/98 A AU 80716/98A AU 8071698 A AU8071698 A AU 8071698A AU 8071698 A AU8071698 A AU 8071698A
Authority
AU
Australia
Prior art keywords
relatedcellular
modulation
signal transduction
protein tyrosine
heteroaryl compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU80716/98A
Inventor
Gerald Mcmahon
John Y. Ramphal
Peng Cho Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of AU8071698A publication Critical patent/AU8071698A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU80716/98A 1997-06-13 1998-06-12 Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction Abandoned AU8071698A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4956097P 1997-06-13 1997-06-13
US60049560 1997-06-13
PCT/US1998/012333 WO1998056376A1 (en) 1997-06-13 1998-06-12 Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction

Publications (1)

Publication Number Publication Date
AU8071698A true AU8071698A (en) 1998-12-30

Family

ID=21960475

Family Applications (1)

Application Number Title Priority Date Filing Date
AU80716/98A Abandoned AU8071698A (en) 1997-06-13 1998-06-12 Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction

Country Status (5)

Country Link
EP (1) EP1007042A4 (en)
JP (1) JP2002512628A (en)
AU (1) AU8071698A (en)
CA (1) CA2293400A1 (en)
WO (1) WO1998056376A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6316635B1 (en) 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6486185B1 (en) 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
AU3363599A (en) * 1998-03-26 1999-10-18 Max-Planck Institut Fur Biochemie Heterocyclic families of compounds for the modulation of tyrosine protein kinase
US6514981B1 (en) 1998-04-02 2003-02-04 Sugen, Inc. Methods of modulating tyrosine protein kinase function with indolinone compounds
AU759226B2 (en) 1998-05-29 2003-04-10 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
US6689806B1 (en) 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
PT1169038E (en) 1999-04-15 2012-10-26 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CA2382789A1 (en) * 1999-08-27 2001-03-08 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatase inhibitors
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
PE20030008A1 (en) 2001-06-19 2003-01-22 Bristol Myers Squibb Co DUAL INHIBITORS OF PDE 7 AND PDE 4
WO2003033496A1 (en) * 2001-10-19 2003-04-24 Transtech Pharma, Inc. Beta-carbolin derivatives as ptp-inhibitors
JP2005513035A (en) * 2001-11-28 2005-05-12 ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・(エス.セー.エール.アー.エス) 5-sulfanyl-4H-1,2,4-triazole derivatives and their use as pharmaceuticals
US7049333B2 (en) 2002-06-04 2006-05-23 Sanofi-Aventis Deutschland Gmbh Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
AR047894A1 (en) 2004-02-25 2006-03-01 Wyeth Corp THIOPHEN DERIVATIVES AS INHIBITORS OF PROTEIN THYROSINE PHOSPHATASE 1B (PTPASA 1B); METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF DISEASES MEDIATED BY PTPASA 1B
WO2017102091A1 (en) 2015-12-18 2017-06-22 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
SG11201900157RA (en) * 2016-07-12 2019-02-27 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
TW201831478A (en) 2016-12-02 2018-09-01 瑞士商赫孚孟拉羅股份公司 Bicyclic amide compounds and methods of use thereof
MX2019008696A (en) * 2017-01-23 2019-09-13 Revolution Medicines Inc Pyridine compounds as allosteric shp2 inhibitors.
CN117327075A (en) 2017-01-23 2024-01-02 锐新医药公司 Bicyclic compounds as allosteric SHP2 inhibitors
EP3652178B1 (en) 2017-07-14 2024-01-24 F. Hoffmann-La Roche AG Bicyclic ketone compounds and methods of use thereof
BR112020004246A2 (en) 2017-09-07 2020-09-01 Revolution Medicines, Inc. shp2 inhibitory compositions and methods for the treatment of cancer
JP7362600B2 (en) 2017-10-11 2023-10-17 エフ. ホフマン-ラ ロシュ アーゲー Bicyclic compounds for use as RIP1 kinase inhibitors
WO2019075265A1 (en) 2017-10-12 2019-04-18 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
RU2020115915A (en) 2017-10-31 2021-12-01 Ф. Хоффманн-Ля Рош Аг BICYCLIC SULFONS AND SULFOXIDES AND METHODS OF THEIR APPLICATION
BR112020009757A2 (en) 2017-12-15 2020-11-03 Revolution Medicines, Inc. polycyclic compounds as allosteric inhibitors of shp2
IL300091A (en) 2018-05-01 2023-03-01 Revolution Medicines Inc C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
IL301346A (en) 2020-09-21 2023-05-01 Landos Biopharma Inc Nlrx1 ligands

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5798374A (en) * 1995-06-07 1998-08-25 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds

Also Published As

Publication number Publication date
EP1007042A4 (en) 2001-07-04
WO1998056376A1 (en) 1998-12-17
JP2002512628A (en) 2002-04-23
CA2293400A1 (en) 1998-12-17
EP1007042A1 (en) 2000-06-14

Similar Documents

Publication Publication Date Title
AU8071698A (en) Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction
AU5468499A (en) 3-methylidenyl-2-indolinone modulators of protein kinase
AU2804597A (en) Synthesis of fluorophore-labeled dna
AU2713799A (en) Modulators of protein tyrosine phosphatases (ptpases)
AU1529997A (en) Substituted histidine inhibitors of protein farnesyltransferase
AU2713699A (en) Modulators of protein tyrosine phosphatases (ptpases)
AU7398194A (en) Oligonucleotide modulation of protein kinase c
AU3363599A (en) Heterocyclic families of compounds for the modulation of tyrosine protein kinase
AU6411698A (en) Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
AU4583796A (en) Determination of software functionality
AU5710398A (en) Thiazole compounds and methods of modulating signal transduction
AU7289696A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AU3443997A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AU3693697A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AU2825899A (en) Modulators of protein tyrosine phosphatases (ptpases)
AU7282998A (en) Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds
AU7342798A (en) Measurement of signal quality
AU1381499A (en) Cell-permeable protein inhibitors of calpain
AU8508798A (en) Polymerization of olefins
AUPO625497A0 (en) Analysis of molecules
AU7622698A (en) Use of indolinone compounds as modulators of protein kinases
AU6250298A (en) Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
AU2217797A (en) Synthesis of indolylmaleimides
AU4157097A (en) Synthesis of bisindolylmalimides
AU5504999A (en) Production of proteins

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase